We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...
Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action. Shares of Verona Pharma plc VRNA have gained 50.7% (versus the S&P 500’s 0.8% ...
Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results